The PRWIRE Press Releases https:// 2017-10-05T22:21:02Z 2017 WHITE PEARL BALL CONTINUES QUEST TO SUPPORT UNDER-FUNDED BRAIN CANCER RESEARCH 2017-10-05T22:21:02Z 2017-white-pearl-ball-continues-quest-to-support-under-funded-brain-cancer-research Sydney, Australia, 6 October 2017: Sydney Neuro-Oncology Group (SNOG) today announced that BANK OF SYDNEY is joining THE WHITE PEARL BALL 2017 as its newest and biggest corporate partner. As part of the Bank’s wider commitment to support the community and charitable organisations, Bank of Sydney will have a significant presence at the Ball and is expected to provide SNOG with significant exposure across its many branches around the State and in ongoing communications with its customers. Having announced that the WHITE PEARL BALL 2017 will take place on November 11th at the Westin Sydney, SNOG will continue its important work in support of brain cancer research. Now in its 3rd year, the event raised $153,000 last year alone through the generous support of guests, donors and sponsors that attended the event. Donations collected at the Ball will fund a new brain cancer research position within SNOG. Established in 2000 by eminent neuro-surgeons, Dr Raymond Cook and Dr Michael Biggs, who were soon after joined by medical oncologist Associate Professor Helen Wheeler, SNOG’s research program is located at the Bill Walsh Cancer laboratory in the Kolling Institute of Medical Research on Sydney’s Royal North Shore Hospital campus. Dr. Cook, Dr. Biggs and Associate Professor Wheeler to this day remain on the Board, directing 100% of donations received to SNOG’s 3 Pillars - Research, Education and Patient Support. Notable contributions have also been made by Assoc. Professor Michael Back, Assoc. Professor Mustafa Khasraw, the recently appointed Dr. Jonathon Parkinson and Board members outside of the medical team. Established by Suzane Peponis-Brisimis in 2015 following the loss of her mother to a brain tumour, The White Pearl Ball has quickly become a much-anticipated event on the Sydney social calendar. “The White Pearl Ball is held in honour of all who have succumbed to brain cancer, those who are currently struggling and all their loved ones. The Ball honours the enormous contribution made by those in the medical profession who treat these patients and support their families and to the researchers who devote their lives to finding solutions,” said Suzane Peponis-Brisimis, Director of SNOG and the White Pearl Fundraiser. In addition to major prize sponsorships, the broader exposure created through the annual charity fundraiser has also seen sponsors such as Alcatel Mobile broadening their involvement with the organisation to include taking up a $35,000 PhD Scholarship, funding promising research by SNOG PhD student Angela Cho. As the leading cause of cancer death in people under 39 years and accounting for more than a third of cancer deaths in children under the age of 10, brain cancer is one of the most under-studied of all cancers. The reality is that brain cancer receives less than 5% of government funds allocated to cancer research funding. “It is truly heart-warming to witness the overwhelming support we receive from our partners and supporters each year, through sponsorships, contributions and donations. Our sincere thanks to all. We are particularly excited about partnering with Bank of Sydney for this Ball and look forward to working closely with the Bank of Sydney team. We also thank Sam Skontos and Alcatel Mobile for the significant donation made at the 2016 Ball and for the ongoing support, as a major prize donor, of the upcoming 2017 Ball.” With the newly signed partnership agreement with SNOG now official, Mr. Michaelas, CEO at Bank of Sydney, was full of praise for SNOG and the important role that it plays. “We would like to congratulate Suzane and her team for all the hard work they put into SNOG. They have inspired Bank of Sydney to get involved, and we want to encourage the community and our customers to support this effort for the well-being of patients whose lives are affected by brain cancer and their families. We are proud of this partnership and we hope that we will help attract more funds and raise awareness for SNOG” said Mr. Michaelas, CEO of Bank of Sydney. The White Pearl Ball will be held at Westin Sydney on November 11th. For tickets, donations, or if you require any further information, please contact Suzane on 0418 238 723 or email her at About the Sydney Neuro-Oncology Group: The Sydney Neuro-Oncology Group (SNOG) is a charitable organisation that aims to improve the management of brain tumours through targeted research, information sharing, constant scrutiny of treatment options and through education and ongoing support for patients and their families. For more information, go to About Bank of Sydney: Bank of Sydney has been operating in Australia under a full Banking Licence since April 2001. With branches in Sydney, Melbourne and Adelaide, we work closely and personally with our customers to understand and exceed their individual needs, which fulfils our vision to become Australia's only true relationship Bank. Bank of Sydney has a remarkable record of investing in and engaging with the broader community as part of its corporate social responsibility initiatives. For further information go to Heart attack study finds more than a quarter of patients have no risk factors 2017-08-28T23:29:37Z heart-attack-study-finds-more-than-a-quarter-of-patients-have-no-risk-factors Risk factors such as high blood pressure, high cholesterol, being diabetic, or cigarette smoking, have long been used as predictors of developing heart disease.  However, a recent study by Heart Research Australia’s Professor Gemma Figtree, published in the European Journal of Preventative Cardiology, has found that there is an increasing proportion of heart attack patients without any standard risk factors, such as high cholesterol. In Professor Figtree’s study, conducted from January 2006 to December 2014 at Royal North Shore Hospital, of the 695 patients who were treated for heart attack, 132 had no known risk factors. The proportion of heart attack patients who had no risk factors in 2006 was 11%, and over the study period, increased to an astounding 27% by 2014. “These results will have important implications for the need to both identify new triggers for heart disease and to better understand the outcomes and best management approach for this group of people”, says Figtree. The cause for this increase in proportion isn’t clear. Despite age mortality rates in Australia decreasing between 1979 and 2009, by 71% for males and 68% for females1 2, coronary heart disease continues to cause a significant burden of disease and remains the leading cause of death in Australia3. “It may be that identification and treatment of standard risk factors like high blood pressure has been successful enough that patients without these treatable conditions are making up a greater proportion of patients having heart attacks. We did find that once these patients have a heart attack, how well they do, for example in terms of risk of dying, is the same as patients with standard risk factors, so it’s just as important that we try to prevent heart attacks in this group. The next step is to identify new ways of diagnosing heart disease to enable early identification and treatment of these patients to better protect them”, says Figtree. Fast facts: - · Each year around 55,000 Australians suffer a heart attack. This equates to one heart attack every 10 minutes. · Heart attack claims 23 lives each day in Australia. · One in four people who die from a heart attack die within the first hour of their first symptom. This study was supported by Heart Research Australia and Sydney University and took place at Royal North Shore Hospital, Sydney. – ENDS – For further information or to schedule an interview: Michelle Kearney,   Heart Research Australia on 0410 922 670 or email  Gut health, immunity and relief from atopic dermatitis for infants: powerful bacteria strain in new consumer health products 2017-08-23T22:38:32Z gut-health-immunity-and-relief-from-atopic-dermatitis-for-infants-powerful-bacteria-strain-in-new-consumer-health-products A potent strain of probiotic bacteria scientifically and clinically demonstrated to reduce eczema symptoms in infants, colonise the gastrointestinal tract and help improve immunity for adults including endurance athletes is now available in a new range of Australian health products. The probiotic strain, Lactobacillus fermentum VRI-003, was originally isolated from a woman with robust gastrointestinal health and is owned by the Australian life sciences company Bioxyne. Lactobacillus fermentum VRI-003 is trademarked ‘PCC®’. This month Bioxyne launched three products formulated with PCC® – Progastrim® for gut health and immunity, Progastrim® + Vitamin C to help reduce the severity and duration of colds and flu symptoms, and proTract® for infants with atopic dermatitis (eczema). Bioxyne’s Scientific Director, cell and molecular biologist Dr Peter French, first started working on the connection between gut microbiome and immune health in 2002. “PCC® has an advantage over many other strains on the market because it produces a thick polysaccharide coat that causes the bacteria to clump, protecting the bacteria from stomach acid and bile and helping it adhere to the walls of the intestinal tract,” Dr French said. “We know from laboratory studies that PCC® is capable of colonising the intestinal tract and stimulating the areas of immune tissue in the small intestine known as Peyer’s Patches. It exhibits superior survival to other probiotics in the acidic (pH 2-4) environment found in the stomach and large intestine and it inhibits a number of human gastrointestinal pathogens.” In double blind, placebo-controlled studies*, PCC® has demonstrated: Reduction of the duration and severity of respiratory infections Reduction of the symptoms of moderate to severe atopic dermatitis (eczema) in infants Boosting of the immune response to the FluVax (flu vaccinations) improved bowel PCC® has a thick, clumpy coat which gives it a survival advantage over other, better known probiotics such as Lactobacillus acidophilus Earlier this year the Therapeutic Goods Administration (TGA) reviewed the evidence supporting the claims for PCC® ’s ability to help improve eczema symptoms in infants and confirmed that the claims comply with the requirements for listing the product on the Australian Register of Therapeutic Goods (ARTG). “Scientists are increasingly proving the connection between the gut microbiome and general health and wellbeing, in ways that extend far beyond just the gastrointestinal tract,” said Dr French. “The question now isn’t whether probiotics are good for you, but which probiotics should be consumed and for what purpose. “Consumers should look for probiotics that are of human origin, resistant to acid and bile, and that have been scientifically and clinically tested for their health claims. We are particularly pleased that the Therapeutic Goods Administration (TGA) earlier this year reviewed the evidence supporting the claims for PCC® ’s ability to help improve eczema symptoms in infants and confirmed that the claims comply with the requirements for listing the product on the Australian Register of Therapeutic Goods (ARTG). Bioxyne’s PCC® products – Progastrim® (RRP AUD$29.95), Progastrim® + Vitamin C (RRP AUD$32.95) and proTract® for atopic dermatitis (RRP AUD$27.95) - can be purchased online at *References to clinical studies cited: Prescott S, Dunstan JA, Hale J, Breckler, Lehmann LH, Weston S, Richmond P, 2005. Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis. Clinical & Experimental Allergy; 35(12):1557-1564. Weston S, Halbert A, Richmond P, Prescott SL, 2005. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Archives of Diseases in Childhood 90:892-897. Cox AJ, Pyne DB, Saunders PU, Fricker PA, 2008. Oral administration of the probiotic Lactobacillus fermentum VRI-003 and mucosal immunity in endurance athletes. British Journal of Sports Medicine 44:222-226. French P, Penny R, 2009. Use of probiotic bacteria as an adjuvant for an influenza vaccine. International Journal of Probiotics and Prebiotics 4(3):175-180. West NP, Pyne DB, Cripps AW, Hopkins WG, Eskesen DC, Jairath A, Christophersen CT, Conlon MA, Fricker PA, 2011. Lactobacillus fermentum (PCC®) supplementation and gastrointestinal and respiratory-tract illness symptoms: a randomised control trial in athletes. Nutrition Journal 10:30. Compelling new lung disease treatment pioneered in Victoria gains global attention alongside top researchers and drug developers 2017-08-20T22:46:22Z compelling-new-lung-disease-treatment-pioneered-in-victoria-gains-global-attention-alongside-top-researchers-and-drug-developers A novel drug treatment emerging from Victoria for the serious lung condition idiopathic pulmonary fibrosis will be spotlighted among world-leading researchers and scientists at the global IPF Summit in Boston (August 20-21). Idiopathic pulmonary fibrosis (IPF) is a rare fibrotic lung condition that causes persistent and progressive scarring of the tiny air sacs (alveoli) in the lungs, with symptoms including shortness of breath and coughing[1]. Lung Foundation Australia estimate that there are around 2,300 new cases diagnosed in in Australia every year[2]. The prognosis of IPF is very poor, with a median survival of only three to five years after diagnosis.[3] There are just two treatments on the market and the disease continues to progress in the majority of patients despite treatment.[4] The new drug, AD-114, is being developed by the Australian biotech AdAlta (ASX:1AD), using AdAlta’s proprietary ‘i-body’ technology. A phase 1 clinical trial will start next year. AD-114 differs from existing treatment options and others currently in clinical development due to its unique mode of action that targets the GPCR chemokine receptor CXCR4. AD-114 has been demonstrated to have both anti-inflammatory and anti-fibrotic activity, hitting a sweet spot for a potential therapy for IPF. The effects of AD-114 have been described by world-leading lung disease researcher Professor Cory Hogaboam (Cedars Sinai Medical Centre) as “impressive” and “providing a compelling case” for treating IPF. AdAlta CEO, Sam Cobb, has been invited to speak at the inaugural summit to showcase the novel therapeutic approach to this largely under-treated area. Ms Cobb will represent the only Australian company in the line-up of academics, international biotech and pharma speakers that include Prof Hogaboam as well as speakers from Genentech, Bristol-Myers Squibb, Celgene and Medimmune. “IPF is a disease with high unmet clinical need and we do believe AD-114 will provide the clinical community and patients with a much-needed new treatment option,” Ms Cobb said. “Although our focus with AD-114 is IPF, AD-114 has the potential to treat a wide-range of fibrotic conditions including wet age-related macular degeneration, of which there are 21,000 new cases diagnosed in Australia each year[5] and non-alcoholic fatty liver disease, which affects around 5.5 million Australians and is a precursor to nonalcoholic steatohepatitis (NASH)[6]. “That we’ve been invited to speak alongside world experts at the inaugural IPF Summit is immensely validating of the critical nature of our work.” AD-114 has received orphan drug status by the FDA, and if approved would be a first-in-class treatment. ‘Orphan’ drugs are those developed to treat a rare medical condition, and they are usually granted accelerated development and regulatory timelines. More about the IPF Summit: More about AdAlta: ***END*** More about AdAlta and its i-body technology: AdAlta is an ASX listed Aussie biotech developing a new class of drugs to treat conditions with a high unmet clinical need. AdAlta is pioneering antibody technology that it calls an ‘i-body’. The size and shape of an i-body gives it an advantage over typical and existing antibody therapies, because it can penetrate and bind to a diverse range of therapeutically-relevant targets. An i-body can also survive extreme conditions. It can be boiled, dropped in acid, (other examples) and yet it remains stable and usable. An i-body, with its long binding loop, is able to target the GPCR chemokine receptor CXCR4, making it applicable to treat a range of clinical conditions including fibrosis. AD-114 is AdAlta’s lead i-body candidate for the treatment of fibrosis. Ilona Marchetta, Media and Digital Specialist @ IR Department +61 416 156 136 | Level 14, 88 Pitt St, Sydney NSW 2000 | Investor and public relations | marketing | corporate and crisis communications About us: IR Department is a boutique investor relations consultancy based in Sydney, specialising in supporting small cap ASX listed companies with their engagement and communication with capital market participants. [1] Lung Foundation Australia [online] at [accessed 3 August 2017] [2] Lung Foundation Australia [online] at [accessed 3 August 2017] [3] ATS, 2000; Raghu et al., 2011 [4] Tzouvelekis A, Bonella F, Spagnolo P, ‘Update on Therapeutic Management of Idiopathic Pulmonary Fibrosis’, Therapeutics and Clinical Risk Management, 2015 Mar 3;11:359-70. doi: 10.2147/TCRM.S69716. eCollection 2015 [5] Macular Degeneration Foundation [online] at [accessed 7 August 2017] [6] The Economic Cost and Health Burden of Liver Disease in Australia (Jan 2013), Gastroenterological Society of Australia) 3D Printing And Dental Product Regulation 2017-08-07T11:25:57Z 3d-printing-and-dental-product-regulation The membership of the Australian Dental Industry Association (ADIA) is reviewing the regulatory issues associated with 3D printed dental products, highlighting how the dental industry pioneers the introduction of new and innovative patient treatment solutions. “Australia’s dental laboratory sector is going through a period of immense change and there is no better example of this than 3D printed crown and bridge work. Something that was a concept only a year or two ago is today a very real option with dental laboratories now having access to this technology, even here in Australia,” said Troy Williams, ADIA Chief Executive Officer. Just as with milling, ADIA believes that 3D printing will give Australia’s dental laboratory sector the ability to compete with cheap overseas imports. “When it comes to competing with imported product, quality is decreasingly an issue as many overseas laboratories use manufacturing inputs than meet Australian regulatory standards for safety. The issue has been labour costs and Australia, with wage rates higher than most nations across south-east Asia, couldn’t compete. 3D printing, just as with milling, changes that,” Mr Williams said. As the peak business organisation representing dental product manufacturers and suppliers, ADIA has been working with the dental laboratory sector to help it understand and use new technologies such as 3D printing. Now ADIA is focussing its efforts on the nation’s regulator of dental products, the Therapeutic Goods Administration (TGA). “ADIA has been asked to provide advice and guidance to the TGA as it sets about developing a regulatory framework for 3D printed dental products. We are pleased that the TGA has engaged with the dental industry, through ADIA, on this matter as it reflects the fact that the regulator acknowledges the role of the dental industry in introducing new and pioneering patient treatment options,” Mr Williams said. In working with the TGA to develop a regulatory approach to 3D printed dental products, ADIA is seeking a regulatory framework for dental products that is based on a risk management approach designed to ensure public health and safety, while at the same time freeing industry from any unnecessary regulatory burden. Breaking News - ASX Listed G Medical Signs Binding MOU for US $67.5M for China Distribution 2017-07-27T00:24:14Z breaking-news-asx-listed-g-medical-signs-binding-mou-for-us-67-5m-for-china-distribution ASX Announcement 27 July 2017 G MEDICAL SIGNS BINDING MOU FOR CHINA DISTRIBUTION VALUED AT US$67.5M •Binding MOU signed with Shandong Boletong Information S&T Co. Ltd. •Agreed terms include call centre cooperation and a minimum purchase order of Smartphone Prizmaunits within the first year. •Medical and ancillary support via Nurse and Physician staffed call centres and ‘Cloud’ services. Mobile health and e-health company G Medical Innovations Holdings Ltd (“G Medical” or the “Company”) is pleased to announce it has executed a Binding Memorandum of Understanding (“Agreement”) between its subsidiary G Medical Innovations Asia Limited and Shandong Boletong Information S&T Co. Ltd. (“Boletong”), for the distribution of G Medical’s products and for call centre and ‘Cloud’ services in the People’s Republic of China. G Medical Smartphone Prizma Purchase Order Pursuant to the terms of the Agreement, Boletong has agreed to purchase a minimum quantity of units within the 1st Year of the G Medical Smartphone Prizma, and to provide associated support services for a minimum period of 60 months. Boletong will pay a pre-determined price for each unit, with the value of the agreement based on the minimum commitments being no less than US$67,500,000. The obligation to acquire the units commences on the granting of the CFDA certification to G Medical, which is currently in process. Support Services 1) Medical Services: Pursuant to the terms of the Agreement, Boletong and G Medical will set up a medical call centreproviding support services from 50-60 Nurses and 3-5 General Practising Physicians. Boletong will be responsible for the recruitment of the Nurses and General Practising Physicians, andthe establishment of the call centre. 2) ‘Cloud’ Subscription and Support Services: Pursuant to the terms of the Agreement, Boletong and/or G Medical will provide; a) Automated Cloud algorithm interpretation services, for biomedical signals 20170727_GMV - Binding MOU for China Distribution Page 2 of 3 b )Level 1 services including, Live and/or automated end-user technical support c) Level 2 services including, hardware (device) support, replacement/repairs Marketing and advertising G Medical agreed to contribute an immaterial portion of the per unit price as marketing and investment for Boletong's promotion of the products and services in China, with such payments to be set-off against payment of the purchase orders by Boletong. Non-competition Boletong and its associations are subject to non-competition restraints for the period of the Agreement, and ending five years after its termination (unless G Medical is found by a Court to have breached the Agreement). These non-competition restraints extend to competing with the products or services of G Medical. G Medical CEO Dr. Yacov Geva, commented: “I am extremely pleased to announce yet another significant relationship for G Medical within the ever-growing and lucrative Chinese territory. To have further increased our purchase commitment for our G Medical Smartphone Prizma devices, over and above our existing agreements, is an exceptional outcome with a key partner in Boletong. This adds further to our robust, multi-year revenue stream for the Company, particularly within the first year of a CFDA approval being granted”. “I have met with the executives of Boletong, and whilst in China have visited their facilities and operations. Boletong operates in 16+ provinces and works with the National Public Health care system and acts as a distributor of medical services for the government. Boletong is currently working with several large healthcare organisations such as Wanda, a medical company which is positioned in the top three in their area, and along with telecom carriers such as China Telecom. Boletong is also supported through investment from a large and reputable group in Beijing. Our team, has invested more than 3 months in bringing this MOU to fruition, during which time we were able to satisfy ourselves as to Boletong's strong financial position, their key government partnerships in place, and the ability to deliver all aspects under our agreement.” “This relationship is a significant strategic partnership, allowing the roll out the Company’s medical and ancillary support services within the Chinese territory, for both our professional call centre and Cloud based systems”. Ends Corporate Advisors Otsana Capital 108 Outram Street West Perth WA 6005 Telephone: +61 8 9486 7244 About Shandong Boletong Information S&T Co., Ltd Shandong Boletong Information S&T Co., Ltd. (Boletong) is a hi-tech medical and healthcare company invested by Beijing Honghui Group which has businesses in medicine, investment, drug store automation system and new energy areas, based in China. Boletong focuses on the production and sales of medical devices, membership healthcare management systems and R&D and applications for the National Basic Public Healthcare Project Solution. Boletong is currently one of the top 16 service providers for the national public healthcare system. Boletong is located in Jinan Hi-tech Technology Development Area, Shandong province. Boletong’s website is About G Medical Innovations G Medical (ASX:GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company brings forth the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity. The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories. For more information on G Medical, please visit Fellowship supports search for new disease treatments 2017-07-23T22:55:35Z fellowship-supports-search-for-new-disease-treatments La Trobe University and leading Australian biotech company AdAlta have received new funding to identify and develop potential treatments for a range of human diseases using the company’s novel class of drugs, known as i-bodies. La Trobe University’s Dr Chris Hocking has been awarded a Science and Industry Endowment Fund (SIEF) Business Fellowship worth $427,000 ($210,000 from the CSIRO), further strengthening the collaboration between La Trobe University and AdAlta. The SIEF Business Fellowship Program aims to build deeper connections and collaborations between researchers and industry, accelerate the adoption of new ideas and technology, while also helping to grow into larger and more profitable organisations. Furthermore, the program provides practical industry experience for early career researchers. The SIEF Fellowship grant will support Dr Hosking’s work with AdAlta’s Chief Scientific Officer, Professor Mick Foley, at the La Trobe Institute for Molecular Science. “Under the SIEF grant we will screen the i-body library to identify and develop new i-body candidates against difficult to access drug targets, such as complex signalling proteins called GPCRs,” Professor Foley said. “Chris is an excellent candidate for the Fellowship because he has extensive experience working with phage displays and screening libraries. Chris brings significant expertise to the AdAlta team.” La Trobe Pro Vice Chancellor Industry and Engagement, Dr Daniel Grant, congratulated Dr Hosking. “La Trobe recognises the importance of engaging with, and building strong partnerships with, innovative companies,” Dr Grant said. “We have had a longstanding and productive relationship with AdAlta and this Fellowship is a great outcome for both parties.” I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treatment of a wide range of human diseases. AdAlta pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, which was discovered initially in sharks and then developed as a human protein. More: Breakthrough in cancer treatments and prevention of subsequent heart failure 2017-05-24T06:47:36Z breakthrough-in-cancer-treatments-and-prevention-of-subsequent-heart-failure Researchers from Heart Research Australia are working on a project that has the incredible potential to make cancer cells more responsive to cancer treatment and potentially eliminate the risk of developing heart failure at a later stage. A commonly used group of cancer treatment drugs called ‘anthracyclines’, which includes the common drug Doxorubicin, although effective can lead to side effects such as heart damage and heart failure. 50% of patients with severe heart failure will die within 1 year of diagnosis.[i] Heart Research Australia’s Chair of Cardiology, Professor Helge Rasmussen, and his co-investigator Dr Chia-chi Liu, are leading a project which has the amazing potential to make a significant improvement in the lives of cancer and cardiac patients. Professor Rasmussen and his team were investigating a group of proteins, called ‘FXYD proteins’ when they realised one of the proteins, FYXD 3, was overexpressed in some cancer cells including breast, pancreas, prostrate and bowel cancer cells. Their test tube experiments proved that the FXYD3 protein protects the cancer cells, making them less responsive to treatments such as Doxorubicin. The team have now developed a peptide (a small protein-like substance) which when applied to some cancer cells, “wipes out” the protective effect of the FXYD 3 protein. “In our studies, when we put the peptide on breast cancer cells and treated it with Doxorubicin, it amplified the effect of the Doxorubicin tenfold.” says Professor Rasmussen. While these results are from test-tube experiments, if Professor Rasmussen and his team could prove this action to have the same effect on some cancers in people, it is possible doctors could use a tenfold lower dose of Doxorubicin (for example) and still get the same results from the treatment. In doing so, this would reduce damage to the heart, and likely eliminate the risk of developing heart failure. Professor Rasmussen is cautiously optimistic, but does acknowledge that this research not only has the potential to reduce damage to the heart, it could also lead to a cure for some cancers. “Heart damage is often now the limiting factor in cancer treatment. You can treat the cancer, but if you damage the heart, it doesn’t always recover. Sometimes people get their cancer treated or even cured, but then they can die from heart failure,” says Professor Rasmussen. “Our work is extremely exciting as it has the potential to drastically change the way we treat cancer.” Fast Facts[ii]: ·      Around 100,000 Australians are living with heart failure.  ·      20–30% of patients with mild to moderate heart failure will die within one year ·      50% of patients with severe heart failure will die within one year ·      Aboriginal and Torres Strait Islander peoples experience chronic heart failure at a younger age and are more likely to die than non-Indigenous Australians ·      Heart failure costs are estimated to be more than $1 billion per annum [i] Watson et al. 2000   [ii] Australian Institute of Health and Welfare. Heart failure… what of the future? Bulletin no. 6. Canberra: AIHW, 2003. World Ovarian Cancer Day: Australia’s only Phase 1 ovarian cancer drug trial recruiting patients 2017-05-07T21:14:01Z world-ovarian-cancer-day-australia-s-only-phase-1-ovarian-cancer-drug-trial-recruiting-patients The only Phase I clinical trial of an ovarian cancer drug in Australia right now is still recruiting participants. The drug under trial, Cantrixil, is believed to be active against difficult-to-target cancer stem cells that are resistant to chemotherapy and lead to cancer recurrence. Three Australian hospitals are participating in the trial – Flinders Medical Centre in South Australia, Westmead Hospital in Sydney, and Icon Cancer Care in South Brisbane – along with three US hospitals. Cantrixil is being developed by listed Australian biotech company, Novogen Ltd (ASX: NRT). The phase 1 trial began in December 2016 and outcomes are expected in early 2018. World Ovarian Cancer Day is May 8. Ovarian cancer is the seventh most common cancer in women and has the lowest survival rate of any women’s cancer. It affects about one in 100 women worldwide, with about 240,000 new cases each year, and around 1,550 women expected to be diagnosed in Australia this year.  “Existing chemotherapy is only curative for about 20 percent of patients,” said Novogen CEO Dr James Garner.  “That Cantrixil has the potential to target and kill cancer stem cells remaining in the body after chemotherapy could lead to a significantly more effective treatment for sufferers. “Although most of the work on Cantrixil to date has focused on ovarian cancer, it’s not out of the question that it could be effective for other cancers.” The Cantrixil trial is being led by Associate Professor Dr Jim Coward, a medical oncologist and Associate Professor of Medicine at UQ School of Medicine and Mater Research, TRI, and based at Icon Cancer Care. Women interested in participating should discuss the Cantrixil trial with their oncologist.    More about Novogen and Cantrixil: ***END***   Media contact: Ilona Marchetta,, 0416 156 136 Tech21 brings parents unlimited fun family time with Evo Play 2017-02-21T01:20:13Z tech21-brings-parents-unlimited-fun-family-time-with-evo-play SYDNEY, 21 February, 2017 – Tech21, the leader in impact protection for mobile devices has launched its new range of cases for the iPad in Australia: Evo Play. “Kids + iPads” isn’t always the safest pairing if your iPad isn’t protected, but it can certainly be one of the most fun for inquisitive minds. Whether it’s watching the latest episode of Peppa Pig or navigating through the back garden jungle discovering new wildlife, iPads can open up a world of exploration, but more often than not, a small chip here or a little crack there means that fun can be cut short. Prolong the play time and keep that shiny new look and feel to your iPad even when little fingers have put it through its paces thanks to tech21’s new iPad case, Evo Play. This comfortable and lightweight case has been designed to offer unbeatable drop protection from up to two metres, and with its iconic design, vibrant colours and handy multi-use handle, this case will remove any glimmer of fear you had in handing over your iPad to your children. This case is constructed almost entirely from tech21’s unique material, FlexShock™ Foam, meaning all sides and surfaces are protected from drops as the material moulds snugly to your iPad. Better still, the case is entirely dishwasher safe, so it’s easy to keep clean, and when it’s on your iPad, its sealed outer shell is abrasion/bite resistant, preventing any bacteria from getting in under the surface. “We’ve designed the all-new Evo Play with kids in mind. We know children love to learn, play and explore, and we recognise iPads are a great way for them to do this. However, they may not love your precious iPad back, so Evo Play is there for you,” comments Jason Roberts, CEO, tech21. “Evo Play is lightweight and comfortable for little hands to hold, yet strong enough to keep your iPad safe from tumbles and drops.” Evo Play is available in pink/purple and blue/green colours from, RRP $79.95 for Apple iPad mini, mini 2, mini 3 & mini 4, and RRP $109.95 for Apple iPad Air 2. Much like all of tech21’s products, Evo Play comes with a simple promise: it’s rigorously tested to work harmoniously with your iPad. Like the technology it’s designed to protect, it uses the latest science, ingenious design and unbeatable user-friendliness to make advanced impact protection possible. Tech21 calls it ‘Protection Made Intelligent’. ### For further information, questions, or cases for review, please contact: Jim Barker, tech21/Poem Phone: +61 418 163 770 Email: High-res images: Download here About tech21 Since 2005, tech21 has been developing the most advanced, scientifically proven cases and screen shields for mobile, tablet and laptop devices worldwide. Tech21 combines science, engineering and British design to create products that address three core consumer benefits: style, protection and performance. As the brand evolves to continue meeting the needs of its consumers, tech21 has developed the most advanced impact protection material on the market – FlexShock™. The ultra-thin and lightweight material absorbs and dissipates force and can withstand drops up to 4 metres. In addition tech21 puts all its products through a rigorous testing program, and in an industry first has partnered with the National Physical Laboratory (NPL) to develop its testing methodology. This ensures that the tests tech21 products have to pass are overseen by independent experts. Tech21 is the number one case brand in the UK. For more information, visit Drink Diet Soft Drink? Start Smoking 2017-02-15T02:41:17Z drink-diet-soft-drink-start-smoking Over one-third (35%) of people never look at or do not understand ingredient lists on food and drink product labels, especially for sweet products, at supermarkets and grocery stores, according to Natvia’s latest global survey ‘Artificial vs Natural Sweeteners – Do you know the difference?’   The vast of majority of people (93%) claimed they understand the negative health effects associated with sugar, however the same cannot be said for the effects of artificial sweeteners on the human body.   Studies have shown that consuming artificial sweeteners such as Aspartame and Acesulfame Potassium (ACE K) in food and drinks such as diet soft drink and ‘zero’ soft drinks may lead to Metabolic Syndrome symptoms such as high blood pressure and weight gain, which are contributors to increased risk of stroke, heart disease and certain cancers. It can be compared to smoking, which raises your heart rate and increases blood pressure, leading to heart disease and lung cancer among other things.   Diabetics also beware, since artificial sweeteners signal your brain to release insulin to take up the sugar that is not there, causing another signal to the brain for more sugar and increased cravings.   As a smoker’s risk of health problems lessens after quitting, the effects associated with artificial sweeteners can be extinguished by converting to a natural sweetener instead.    A natural sweetener such as stevia is unique as it does not contain sugar and therefore has no effect on blood sugar levels or the Glycaemic Index. Studies show natural sweeteners may help to reduce blood pressure and oxidative stress in the body.   75% of respondents claimed to know the difference between a natural and artificial sweetener, so why is it taking so long for people to make the change? Supporting infographic for use: About Natvia: Natvia is an Australian born company and the leading 100% natural sweetener made from stevia, which is sweeter than sugar but doesn’t have any effect on blood glucose levels. Stocked internationally and a driving force behind inspiring people to live a better life, Natvia provides its audience and customers with sugar free recipe ideas. It can be used for baking, cooking, in tea, coffee, smoothies and other delicious treats. Natvia is packaged in the form of on the go tablets, baking packs, sachets and canisters. ///ENDS///     For more information please contact: Brent Switkowski                                                        Miriam Indries  PR Coordinator                                                            Marketing Manager                                                  03 9521 1553                                                              0432 685 135 NZ CHIROPRACTORS READY TO PLAY PART IN REDUCING HARM FROM FALLS 2016-12-18T20:18:51Z nz-chiropractors-ready-to-play-part-in-reducing-harm-from-falls-1 The New Zealand Chiropractors’ Association (NZCA) has welcomed calls by the Health Quality & Safety Commission, published in the latest issue of the New Zealand Medical Journal[1], for an integrated, multidisciplinary approach to the prevention of falls, one patient at a time.   Chiropractor and NZCA spokesperson Dr Cassandra Fairest explains: `We fully support the need for individualised responses to prevent falls one patient at a time, and for leadership responses that promote an integrated approach to reducing the risk of falls in older people. Chiropractors are uniquely placed within the healthcare spectrum as they support better spine and nervous system health which has demonstrated positive effects on balance in the older population,  and therefore this would help reduce the future need for a massive increase in healthcare costs.   `A growing body of research suggests that chiropractic care may slow the rate of functional decline as you age, preserve your autonomy, improve your well-being and reduce accidents. It could also save New Zealand millions of dollars in the longer term[2].’   Falls are the leading cause of injury related hospital admissions and death in the over fifties.  In 2014, 205,000 New Zealanders aged 50 or over had an ACC claim accepted for a fall-related injury, representing a 20% increase since 2011[3].   Dr Kelly Holt, Dean of Research at the New Zealand College of Chiropractic and his team recently published the results of a research study in New Zealand which has shown chiropractic care in a group aged 65 to 89 can significantly impact several factors that influence the prevention of falls2.’   Dr Fairest explains: ‘After twelve weeks the group who received chiropractic care had increased ability in identifying where their ankle joint was when they closed their eyes. This is likely to prevent falls, as your brain will be more accurately aware of where your foot is without you having to look at your foot while walking.’   Dr Holt and his fellow researchers in the New Zealand study also found that older adults who received 12 weeks of chiropractic care were able to take a step much faster than the control group not receiving chiropractic care. This is an important finding, because being able to take a fast step to correct balance can assist in fall prevention. Additionally, this study showed that the older adults who received chiropractic care were able to simultaneously process visual and auditory information more accurately in their brain.   Dr Fairest adds: `This is known to be important and relevant when it comes to preventing falls. Science has shown that as we age we appear to lose our ability to process multiple lots of sensory information accurately and that this leads to distractions that may cause falls’.   `We want to encourage New Zealanders to visit their chiropractor to ensure that their spines and nervous systems are functioning well. A local NZCA chiropractor will be able to provide advice on ways to improve posture, enhance coordination and support a healthy spine. A healthy spine and well-functioning nervous system is important for overall health and wellbeing.’     Ends   Further Information: Dr Cassandra Fairest, Chiropractor 021 242 3073 or Peter Boyes 027 554 0500 or   [1] NZMJ 2 December 2016, Vol 129 No 1446 ISSN 1175-8716 [2] Holt, Kelly R et al, “Effectiveness of Chiropractic Care to Improve Sensorimotor Function Associated With Falls Risk in Older People: A Randomized Controlled Trial,” Journal of Manipulative and Physiological Therapeutics.  [3] Health Quality & Safety Commission. New Zealand Atlas of Healthcare Variation. Falls. http://www.hqsc.govt. nz/our-programmes/ health-quality-evaluation/ projects/atlas-of-healthcare-variation/ falls/.   Australian digital health platform HealthKit partners with Data61’s Coviu, giving video consultation capability to more than 15,000 Australian health practitioners 2016-08-23T22:05:54Z australian-digital-health-platform-healthkit-partners-with-data61-s-coviu-giving-video-consultation-capability-to-more-than-15-000-australian-health-practitioners MELBOURNE, AUSTRALIA - 24 August 2016. HealthKit (, the leading Australian digital health platform for practitioners and patients today announces a technology partnership with Coviu, a CSIRO Data61 startup, to integrate its browser-based telehealth platform, giving video consultation capability to HealthKit’s 15,000 Australian health practitioners. HealthKit is a cloud-based platform that combines practice management software for private practitioners (medical specialists, GPs, and allied health) with an integrated directory and portal for patients to track and manage their health. Bringing these services together makes healthcare efficient, effective and accessible, and generates a wealth of valuable anonymised data. Earlier in 2016, HealthKit closed a Series A investment for $A1.6m to fund international growth. Coviu launched its WebRTC-based video platform in November 2015, which allows for in-browser video conferencing and exchange of documents and images such as medical imaging, without the need to use an external program or download an app such as Skype. The platform is fully encrypted end-to-end, making it one of the most secure video conferencing technologies in the world. Alison Hardacre, HealthKit co-founder said, “This exciting partnership allows HealthKit’s practitioners to add telehealth services to their existing service offering by providing online video consultation capability. Telehealth is the next major trend in healthcare globally. The American Medical Association recently released their first guidelines for telehealth which further legitimises and endorses the use of telehealth in mainstream healthcare. Telehealth can positively impact broader health outcomes; providing access to critical health services to rural and remote Australia, where the life expectancy is up to four years shorter than for those in cities. For HealthKit, the introduction of extensive telehealth capability adds to our comprehensive functionality for practitioners and patients, and further boosts our pool of anonymised health data. For patients, the technology partnership with Coviu puts their doctor at their fingertips - saving on travel and waiting time. Telehealth is a game-changer for the elderly, people with disabilities, and for parents facing logistical difficulties getting their kids to the doctor. It also provides incredible convenience for people who are working to see a practitioner without needing to leave the office to do so” Coviu Project Director and Co-Founders Dr. Silvia Pfeiffer said, “Coviu’s goal is to enable all primary and allied health practitioners in Australia to offer video consultation functionality. To make video consultations part of workflows, we made it simple for our partners to integrate our technology into their systems. Our user interface has a big focus on usability to make it really accessible to practitioners and the broader public.” Online consultations functionality is now being rolled out across HealthKit’s practitioner network. - ends - For more information - HealthKit: Alison Hardacre, Co-Founder, HealthKit, Kate Dinon, KDPR, +61 487 328 738 For more information - Coviu: Dr Silvia Pfeiffer, Coviu Project Director and Co-Founder,, +61 401 384 041 Elizabeth McKenzie, Communications Manager at DATA61,, +61 2 9490 5598, +61 403 359 105 Images: About HealthKit HealthKit is on a mission to digitise the entire health ecosystem - only 11% of doctors globally use software. HealthKit is a global health platform for patients and practitioners, providing practice management software to private practices customised to any profession and health system, and integrated services to patients and consumers, such as searchable directories and clinical tools to manage patient health. Bringing services together makes healthcare efficient, effective and accessible and creates valuable data. Since its launch in 2012, HealthKit has attracted more than 15,000 practitioners to its practice management software and in tandem has become Australia’s largest searchable directory, with more than 220,000 practitioner profiles. To date, 90% of the practitioner base are located in Australia, with the remaining 10% spread across more than 40 countries. About Coviu Coviu is an emerging startup out of Data61/CSIRO (formerly NICTA) offering an innovative digital service delivery platform underpinned by extensive WebRTC research and high level user experience design. Coviu offers feature rich video collaboration using standard consumer hardware to enable experts in government, health or education services to meet with clients over consumer Internet. The interface is easily adapted to custom document formats and use cases. For more information visit INTERNATIONAL RESEARCHERS SAY CHIROPRACTIC MAY MAKE YOUR MIND SHARPER 2016-07-30T21:38:08Z international-researchers-say-chiropractic-may-make-your-mind-sharper Ground-breaking research indicates that chiropractic care may make your brain function better, according to the New Zealand Chiropractors’ Association (NZCA). A collaborative study on the effects of manipulation of the spine on brain function between Denmark’s Aalborg University, the New Zealand Centre for Chiropractic Research, the Health & Rehabilitation Research Institute, AUT University and University of Ontario Institute of Technology, published earlier this year  in the journal Neural Plasticity suggests that, at least in part, the mechanisms by which spinal manipulation improves performance are due to a change in processing of information at the prefrontal cortex. Dr Cassandra Fairest, chiropractor and spokesperson for the NZCA explains: `The focus of chiropractic care is on the health and integrity of the nervous system. The health and function of the spine affects the entire nervous system. We already know that the spinal cord is an integral part of the central nervous system and processes information just like parts of the brain do  and the latest New Zealand research into the effects of chiropractic care suggests that it may have an important role to play in improving executive function.’  Executive function is the mechanism by which the brain integrates and coordinates the operations of multiple neural systems to solve problems and achieve goals based on the ever-changing environment around us.  The researchers point out that executive function is considered to be a product of the coordinated operation of various neural systems and is essential for achieving any particular goal. The prefrontal cortex is believed to be the main brain structure responsible for enabling this coordination and control. It requires planning a sequence of subtasks to accomplish a goal, focusing attention on relevant information as well as inhibiting irrelevant distractors, being able to switch attention between tasks, monitoring memory, initiation of activity, and responding to stimuli.  Dr Fairest adds: `A change in prefrontal activity following chiropractic care may therefore explain and/or link some of the varied improvements in central nervous system function previously observed in other research, such as improved joint position sense error, reaction time , cortical processing, cortical sensorimotor integration, reflex excitability, motor control, and lower limb muscle strength . `All this research, much of it from the New Zealand College of Chiropractic Centre for Chiropractic Research  and funded by the Australian Spinal Research Foundation strongly suggests that chiropractic care/adjustments can significantly improve brain­-body communication and coordination.’ According to Dr Fairest: `We know that chiropractic care assists brain function in many ways, one of which is proprioceptive function (perception) and this improves the accuracy of the internal brain map so your brain accurately knows what is occurring within your body and the surrounding environment continuously.  Environment relates to the processes inside the body, as well as its immediate surroundings’.  ­Ends­ eVestigator® Cyber Forensics Expert Simon Smith says 'POKÉMON NO' to Augmented Reality 2016-07-26T09:36:16Z evestigator-r-cyber-forensics-expert-simon-smith-says-pokemon-no-to-augmented-reality PRESS RELEASE 26/7/2016 CYBER FORENSIC EXPERT ISSUES NATIONAL SECURITY WARNING EVESTIGATOR CYBER FORENSICS EXPERT SIMON SMITH SAYS 'POKÉMON NO' TO AUGMENTED REALITY Availability for further interview / discussion TV – Aus-Wide – 24hrs notice, Radio – 8 hrs notice –© Simon Smith 0410 643 121 - Written consent needed to reuse/quote from this release. Contact: Simon Smith. (eVestigator® aka Simon Smith, an expert in Cyber stalking and Cybercrime Investigations and a Master in Computer Digital Forensics says that our children and teenagers are severely at risk of physical, sexual and psychological harm from the use of this game) © SIMON SMITH - EVESTIGATOR® URGENT PUBLIC MEDIA RELEASE © - CREDIT & PERMISSION ASKED FOR IN WRITING BEFORE USE eVestigator®, Computer Forensics Cyber Expert – CHFI, Computer Hacking Forensics Investigator, Private Investigator Phone: 1800 CYBER I, Direct: 0410 643 121 Melbourne, July 26, 2016: Mr. Simon Smith of, and, a top Australian Computer Forensics expert, Cyber-crime Investigator, cyber-stalking expert and programmer of 25 years knows all too well the other side of what it looks like in a courtroom when somebody is the victim of cyber-stalking or white collar crime. He is often giving forensic evidence or reports in relation to high-tech computer crimes as an expert witness or private investigator. He has also worked on cases involving child pornography and the police, and is a strong advocate against Cyber-bullying, Cyber-stalking and Cyber-crimes civilly and criminally, and has helped hundreds of people attain justice and resolution in many cases, especially involving children and violence and forensic impersonation. As a Commonwealth Appointed Family Dispute Practitioner, with the very difficult job of dealing with awkward family disputes along with his specialised cyber forensic knowledge and cases as a private investigator, he speaks of cases where he has dealt with kidnapping, abductions, cults, poisoning and more. Never, however did Mr. Smith predict that what he calls “Cybergeddon™” would come so soon. Simon explains the term “augmented reality” in the new Pokémon game as going too far. “Imagine walking in a straight line and a cartoon character appears in front of you. That is simply what it is. A technology that draws a computer-generated image on a user's view of the real world (knowing on their phone where they are via the GPS), in this case a character or an object named a Pokémon. It then uses the camera on the back of the phone to paint the background, so it looks like there is a cartoon in your view”. He further says, “the earth is made up of various known areas comprising longitude and latitudes. These are known to the game and randomized, and the object of the game is to find Pokémon and physically step within a meter or so of it to interact, and likewise, collect other objects in the game”. He further explains that “these objects are randomly placed on or around you are on earth without any data verification”. Mr. Smith asks you to imagine your child, or teenage son or daughter walking around with head buried in their phone, jumping complete stranger’s fences, in and out of their neighbourhood, exploring places they shouldn’t be – knocking on stranger’s doors, asking if they can collect a Pokémon from their backyard. Then he asks you to “stop imagining because it is actually happening now”. He then asks you to imagine a “destination” that may be randomly picked in the game for your child to visit. Imagine if one of these stops was say in the case of America, “The Windsor Hotel in Phoenix Arizona”. Would you be concerned if you knew that in this instance, this was a halfway house for sex offenders? He also asks you to not imagine, and says, “Well, that happened too!” Mr. Smith deals with reverse cyber stalking cases all the time. Finally, he asks you to imagine that a group of bullies had a special directory which told them where a victim would be going at a certain time. It would allow them to lay a trap, and wait for the prey. Of course Mr. Smith says, “let’s not imagine - that actually happened too. In fact, only a few days after launch a gamer was robbed at gun point in dangerous unchartered neighbourhoods because the attackers knew he’d be chasing Pokémon they used game bonuses to lure there.” Mr. Smith, both as an IOS and Android programmer and cyber stalking forensic investigator and court expert witness strongly warns the community and rates this at a risk of 10/10 to any parent. He states that It could be used as a directory for stalkers and paedophiles to find children, and cause danger to society in an already understaffed and underqualified area of policing, being organised cyber-crime. Mr. Smith further states that it could even be considered the “Yellow Pages of Children and Teens” for Sex Predators – it could be easily argued that this is in fact no longer “augmented”. Mr. Smith strongly advises everyone to be conscious of the line that has just been crossed – and understand that crime is still crime even if it is hidden in what appears to be a ‘fun super-artificial method of game play’. “It is not a game anymore”, Mr. Smith strongly states. “It’s dangerous, it’s real and it is most likely in the hands of your children now”. Mr. Smith feels very passionate about the dangers he sees, in his expert opinion, he would strongly “recommend parents remove the game after doing further research” as he truly believes it crosses the line by masking serious cybercrime. He finishes by stating that, “It is ironic that people used to be afraid of the psychological effect of what violent artificial games may have on people, now I’m saying backed by evidence and experience, they should really be worried – because it has now crossed over to reality." This is general advice and not to be taken as legal advice and naturally, not all game players are likely to contribute to this conduct, this is an opinion expressed by me raising concern in this area of augmented reality. eVestigator®, Simon Smith Computer Forensics Cyber Expert – CHFI, Computer Hacking Forensics Investigator, Private Investigator © SIMON SMITH - EVESTIGATOR® URGENT PUBLIC MEDIA RELEASE © CREDIT & PERMISSION ASKED FOR IN WRITING BEFORE USE Please consider the environment before printing